These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 28093010)

  • 1. Correction to: Factors influencing the fabrication of albumin-bound drug nanoparticles (ABDns): Part I. Albumin-bound betulinic acid nanoparticles (ABBns).
    J Microencapsul; 2016 Dec; 33(8):i-ii. PubMed ID: 28093010
    [No Abstract]   [Full Text] [Related]  

  • 2. Factors influencing the fabrication of albumin-bound drug nanoparticles (ABDns): part I. Albumin-bound betulinic acid nanoparticles (ABBns).
    Srivari Y; Chatterjee P
    J Microencapsul; 2016 Dec; 33(8):689-701. PubMed ID: 27707051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction to: Erukula and Chatterjee, Factors influencing the fabrication of albumin-bound drug nanoparticles (ABDns): Part II. Albumin-bound carbamazepine nanoparticles (ABCns).
    J Microencapsul; 2016 Sep; 33(6):i-ii. PubMed ID: 27744740
    [No Abstract]   [Full Text] [Related]  

  • 4. Factors influencing the fabrication of albumin-bound drug nanoparticles (ABDns): Part II. Albumin-bound carbamazepine nanoparticles (ABCns).
    Erukula SV; Srivari Y; Chatterjee P
    J Microencapsul; 2016 Sep; 33(6):524-534. PubMed ID: 27549905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adsorption/desorption of human serum albumin at the surface of poly(lactic acid) nanoparticles prepared by a solvent evaporation process.
    Verrecchia T; Huve P; Bazile D; Veillard M; Spenlehauer G; Couvreur P
    J Biomed Mater Res; 1993 Aug; 27(8):1019-28. PubMed ID: 8408114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient delivery of therapeutic agents by using targeted albumin nanoparticles.
    Kouchakzadeh H; Safavi MS; Shojaosadati SA
    Adv Protein Chem Struct Biol; 2015; 98():121-43. PubMed ID: 25819278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Albumin nanoparticles for the delivery of gabapentin: preparation, characterization and pharmacodynamic studies.
    Wilson B; Lavanya Y; Priyadarshini SR; Ramasamy M; Jenita JL
    Int J Pharm; 2014 Oct; 473(1-2):73-9. PubMed ID: 24999053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Albumin-based nanoparticles as potential controlled release drug delivery systems.
    Elzoghby AO; Samy WM; Elgindy NA
    J Control Release; 2012 Jan; 157(2):168-82. PubMed ID: 21839127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A nontoxic disulfide bond reducing method for lipophilic drug-loaded albumin nanoparticle preparation: formation dynamics, influencing factors and formation mechanisms investigation.
    Jiang L; Xu Y; Liu Q; Tang Y; Ge L; Zheng C; Zhu J; Liu J
    Int J Pharm; 2013 Feb; 443(1-2):80-6. PubMed ID: 23291446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxorubicin and paclitaxel co-bound lactosylated albumin nanoparticles having targetability to hepatocellular carcinoma.
    Thao LQ; Lee C; Kim B; Lee S; Kim TH; Kim JO; Lee ES; Oh KT; Choi HG; Yoo SD; Youn YS
    Colloids Surf B Biointerfaces; 2017 Apr; 152():183-191. PubMed ID: 28110040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Albumin-bound nanoparticles of practically water-insoluble antimalarial lead greatly enhance its efficacy.
    Ibrahim N; Ibrahim H; Dormoi J; Briolant S; Pradines B; Moreno A; Mazier D; Legrand P; Nepveu F
    Int J Pharm; 2014 Apr; 464(1-2):214-24. PubMed ID: 24412521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fabrication of a nanocarrier system through self-assembly of plasma protein and its tumor targeting.
    Gong G; Zhi F; Wang K; Tang X; Yuan A; Zhao L; Ding D; Hu Y
    Nanotechnology; 2011 Jul; 22(29):295603. PubMed ID: 21673386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Properties and stability of blueberry anthocyanin--bovine serum albumin nanoparticles.
    Chen J; Tao X; Zhang M; Sun A; Zhao L
    J Sci Food Agric; 2014 Jul; 94(9):1781-6. PubMed ID: 24302118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic advantage of inhaled tacrolimus-bound albumin nanoparticles in a bleomycin-induced pulmonary fibrosis mouse model.
    Seo J; Lee C; Hwang HS; Kim B; Thao le Q; Lee ES; Oh KT; Lim JL; Choi HG; Youn YS
    Pulm Pharmacol Ther; 2016 Feb; 36():53-61. PubMed ID: 26768967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct comparison of two albumin-based paclitaxel-loaded nanoparticle formulations: is the crosslinked version more advantageous?
    Li C; Li Y; Gao Y; Wei N; Zhao X; Wang C; Li Y; Xiu X; Cui J
    Int J Pharm; 2014 Jul; 468(1-2):15-25. PubMed ID: 24709221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human serum albumin (HSA) nanoparticles stabilized with intermolecular disulfide bonds.
    Wang W; Huang Y; Zhao S; Shao T; Cheng Y
    Chem Commun (Camb); 2013 Mar; 49(22):2234-6. PubMed ID: 23396533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.
    Robidoux A; Buzdar AU; Quinaux E; Jacobs S; Rastogi P; Fourchotte V; Younan RJ; Pajon ER; Shalaby IA; Desai AM; Fehrenbacher L; Geyer CE; Mamounas EP; Wolmark N
    Clin Breast Cancer; 2010 Feb; 10(1):81-6. PubMed ID: 20133263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of a BALB/c-Nu Mouse Model of Invasive Bladder Carcinoma and Preliminary Studies on the Treatment of Bladder Tumors through Internal Iliac Arterial Infusion of Albumin-Bound Arsenic Trioxide (As2O3).
    Li Y; Yu G; Li Q; Wang W; Shen X; Liu H; Liu R
    PLoS One; 2015; 10(4):e0124959. PubMed ID: 25915411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles.
    Kratz F
    J Control Release; 2008 Dec; 132(3):171-83. PubMed ID: 18582981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells.
    Altintas I; Heukers R; van der Meel R; Lacombe M; Amidi M; van Bergen En Henegouwen PM; Hennink WE; Schiffelers RM; Kok RJ
    J Control Release; 2013 Jan; 165(2):110-8. PubMed ID: 23159529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.